1-7 of 7
Juan C. Varela
Close
Sort by
Journal Articles

Phase 1/2 Study of Nexi-002 Autologous Multi-Antigen-Specific CD8+ T Cells for the Treatment of Relapsed or Refractory Multiple Myeloma

Robert D Knight, Myo Htut, Juan C. Varela, Andrew Kin, Vineetha Edavana, Emily Lu, Sojung Kim, Lauren Suarez, Mathias Oelke, Daniel Bednarik
Journal: Blood
Blood (2021) 138 (Supplement 1): 2824.
https://doi.org/10.1182/blood-2021-152185
Published: 2021
Journal Articles

Outreach: Results from a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) Administered As Inpatient (Inpt) or Outpatient (Outpt) Treatment in the Nonuniversity Setting in Patients (Pts) with R/R Large B-Cell Lymphoma (LBCL)

John E. Godwin, Bassam Mattar, Michael Maris, Carlos Bachier, Don Stevens, Daanish Hoda, Juan C. Varela, Mohamad Cherry, Suzanne Fanning, James Essell, Habte Yimer, Jay Courtright, Jeff P. Sharman, Ricardo Espinola, Connor Mailley, Ariel Avilion, Ken Ogasawara, San-San Ou, Paul Shaughnessy
Journal: Blood
Blood (2021) 138 (Supplement 1): 1762.
https://doi.org/10.1182/blood-2021-148792
Published: 2021
Journal Articles

Phase 1/2 Study of Nexi-001 Donor-Derived Multi-Antigen Specific CD8+ T Cells for the Treatment of Relapsed Acute Myeloid Leukemia (AML) after Allogeneic Hematopoietic Transplantation

Monzr M. Al Malki, Sumithira Vasu, Dipenkumar Modi, Miguel-Angel Perales, Lucy Y Ghoda, Donna Bui, Vineetha Edavana, Emily Lu, Sojung Kim, Lauren Suarez, Mathias Oelke, Daniel Bednarik, Robert D Knight, Juan C. Varela
Journal: Blood
Blood (2021) 138 (Supplement 1): 4819.
https://doi.org/10.1182/blood-2021-152419
Published: 2021
Journal Articles

Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) in the Nonuniversity Setting: Initial Results from the Outreach Study

John E. Godwin, MD, Cesar O. Freytes, MD, Michael Maris, MD, Don A. Stevens, MD, Daanish Hoda, MD, Bassam Mattar, MD, Juan C. Varela, MDPhD, Mohamad Cherry, MDMS, James Essell, MD, Jay Courtright, MD, Suzanne R. Fanning, DO, Habte A. Yimer, MD, Nikolaus S. Trede, MD PhD, Marina Youssef, PharmD, James Lymp, PhD, Carlos Bachier, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 50–52.
https://doi.org/10.1182/blood-2020-136640
Published: 2020
Journal Articles

Preliminary Results of the First-in-Human Study of Nexi-001, a Multi-Antigen Specific CD8+ T Cell Product, in Acute Myeloid Leukemia (AML) Patients with Relapsed Disease after Allogeneic Hematopoietic Cell Transplantation (Allo-HSCT) Demonstrate Early Signs of Safety, Tolerability and Robust Immune Responses

Monzr M. Al Malki, MD, Miguel-Angel Perales, MD, Dipenkumar Modi, MD, Sumithira Vasu, MDMBBS, Megan Nelson, RN, Donna Bui, Sojung Kim, Ruipeng Wang, Emily Lu, Mathias Oelke, Han Myint, MDFRCPath,FRCP, Juan C. Varela, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 31–33.
https://doi.org/10.1182/blood-2020-139342
Published: 2020
Journal Articles

Enrichment and Expansion of Mart-1, NY-ESO and WT1 Specifc CD8+ T Cells Using Nano-Particle Artificial Antigen Presenting Cells (Nano-aAPCs)

Juan C. Varela, MD PhD, Karlo Perica, Christian Schuetz, PhD, Joan Bieler, PhD, Carl Haupt, Mathias Oelke, PhD, Jonathan Schneck, MDPhD
Journal: Blood
Blood (2014) 124 (21): 2443.
https://doi.org/10.1182/blood.V124.21.2443.2443
Published: 2014
Journal Articles

Redirection of Antigen-Specific T Cells to Tumor Cells Using Nanoparticle-Based Antigen-Specific Redirectors (ATRs)

Christian Schuetz, PhD, Juan C. Varela, MD PhD, Karlo Perica, Carl Haupt, Mathias Oelke, PhD, Jonathan Schneck, MDPhD
Journal: Blood
Blood (2014) 124 (21): 2753.
https://doi.org/10.1182/blood.V124.21.2753.2753
Published: 2014